|
US6544769B1
(en)
*
|
1996-12-13 |
2003-04-08 |
Schering Corporation |
Compostions comprising viruses and methods for concentrating virus preparations
|
|
US20080261289A1
(en)
*
|
1996-12-13 |
2008-10-23 |
Schering-Plough Corporation |
Compositions comprising viruses and methods for concentrating virus preparations
|
|
AU773834B2
(en)
*
|
1998-12-03 |
2004-06-10 |
Avigen, Inc. |
Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
|
|
US6759050B1
(en)
|
1998-12-03 |
2004-07-06 |
Avigen, Inc. |
Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
|
|
US6225289B1
(en)
*
|
1998-12-10 |
2001-05-01 |
Genvec, Inc. |
Methods and compositions for preserving adenoviral vectors
|
|
KR20020013521A
(ko)
*
|
1999-04-09 |
2002-02-20 |
추후제출 |
감염성 재조합 아데노바이러스 보존용 조성물
|
|
FR2791999B1
(fr)
*
|
1999-04-09 |
2001-09-07 |
Aventis Pharma Sa |
Composition destinee a la conservation d'adenovirus recombinants infectieux
|
|
US7456009B2
(en)
|
2000-03-07 |
2008-11-25 |
Merck & Co., Inc. |
Adenovirus formulations
|
|
JP5118798B2
(ja)
*
|
2000-03-07 |
2013-01-16 |
メルク・シャープ・エンド・ドーム・コーポレイション |
アデノウイルス製剤
|
|
AU2001256675A1
(en)
*
|
2000-05-10 |
2001-11-20 |
Mitsubishi Pharma Corporation |
Method of preparing virus vector
|
|
EP1453536A4
(en)
|
2001-12-12 |
2009-08-26 |
Mayne Pharma Int Pty Ltd |
COMPOSITION FOR PRESERVING VIRUSES
|
|
CA2469721A1
(en)
*
|
2002-01-18 |
2003-07-31 |
Schering Aktiengesellschaft |
Stabilized formulations of adenovirus
|
|
KR100507794B1
(ko)
*
|
2003-02-11 |
2005-08-17 |
한미약품 주식회사 |
고농도 레트로 바이러스 현탁액 제조 방법
|
|
WO2005052116A2
(en)
*
|
2003-11-19 |
2005-06-09 |
Merck & Co., Inc. |
Preservative-containing virus formulations
|
|
WO2005080556A2
(en)
*
|
2004-02-23 |
2005-09-01 |
Crucell Holland B.V. |
Virus purification methods
|
|
GB0502661D0
(en)
*
|
2005-02-09 |
2005-03-16 |
Stabilitech Ltd |
A desiccated product
|
|
AU2006233800B2
(en)
*
|
2005-04-11 |
2011-07-07 |
Crucell Holland B.V. |
Virus purification using ultrafiltration
|
|
CN1961961B
(zh)
*
|
2005-11-11 |
2010-05-26 |
深圳市源兴生物医药科技有限公司 |
一种药物制剂及其制备方法
|
|
NZ593235A
(en)
|
2008-11-03 |
2013-02-22 |
Crucell Holland Bv |
Method for the production of recombinant adenovirus serotype 35
|
|
PL2536829T3
(pl)
|
2010-02-15 |
2016-09-30 |
|
Sposób wytwarzania wektorów adenowirusowych Ad26
|
|
WO2012038367A1
(en)
|
2010-09-20 |
2012-03-29 |
Crucell Holland B.V. |
Therapeutic vaccination against active tuberculosis
|
|
CA2809463C
(en)
|
2010-09-27 |
2021-05-25 |
Crucell Holland B.V. |
Heterologous prime boost vaccination regimen against malaria
|
|
CA2819236A1
(en)
|
2010-12-02 |
2012-06-07 |
Oncolytics Biotech Inc. |
Lyophilized viral formulations
|
|
AU2011336413B2
(en)
|
2010-12-02 |
2015-01-22 |
Oncolytics Biotech Inc. |
Liquid viral formulations
|
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
|
CN104379733B
(zh)
|
2012-03-12 |
2016-01-20 |
克鲁塞尔荷兰公司 |
具改变末端的重组腺病毒群
|
|
MY169352A
(en)
|
2012-03-22 |
2019-03-25 |
Janssen Vaccines & Prevention Bv |
Vaccine against rsv
|
|
US9125870B2
(en)
|
2012-03-22 |
2015-09-08 |
Crucell Holland B.V. |
Vaccine against RSV
|
|
WO2014009433A1
(en)
|
2012-07-10 |
2014-01-16 |
Transgene Sa |
Mycobacterium resuscitation promoting factor for use as adjuvant
|
|
EA029492B1
(ru)
|
2012-07-10 |
2018-04-30 |
Трансген Са |
Вакцина на основе микобактериальных антигенов
|
|
EP3488864A1
(en)
|
2013-04-25 |
2019-05-29 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion rsv f polypeptides
|
|
EP3010931B1
(en)
|
2013-06-17 |
2018-06-13 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion rsv f polypeptides
|
|
WO2015104380A1
(en)
|
2014-01-09 |
2015-07-16 |
Transgene Sa |
Fusion of heterooligomeric mycobacterial antigens
|
|
US9721484B2
(en)
|
2014-06-23 |
2017-08-01 |
Humanetics Innovative Solutions, Inc. |
Shoulder kit assembly for crash test dummy
|
|
CN120555373A
(zh)
|
2014-07-16 |
2025-08-29 |
特兰斯吉恩股份有限公司 |
用于表达免疫检查点调节因子的溶瘤病毒
|
|
US10008130B2
(en)
|
2014-09-17 |
2018-06-26 |
Humanetics Innovative Solutions, Inc. |
Omni-directional shoulder assembly for crash test dummy
|
|
WO2016128542A1
(en)
|
2015-02-13 |
2016-08-18 |
Transgene Sa |
Immunotherapeutic vaccine and antibody combination therapy
|
|
WO2016131945A1
(en)
|
2015-02-20 |
2016-08-25 |
Transgene Sa |
Combination product with autophagy modulator
|
|
SI3283634T1
(sl)
|
2015-04-14 |
2019-08-30 |
Janssen Vaccines & Prevention B.V. |
Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem
|
|
EP3319634B1
(en)
|
2015-07-07 |
2019-08-21 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion rsv f polypeptides
|
|
CN116059336A
(zh)
|
2015-07-07 |
2023-05-05 |
扬森疫苗与预防公司 |
针对rsv的疫苗
|
|
MD3439672T2
(ro)
|
2016-04-05 |
2021-04-30 |
Janssen Vaccines & Prevention Bv |
Proteine F RVS de pre-fuziune solubile stabilizate pentru utilizare în profilixia infecţiilor cu RSV
|
|
PE20190433A1
(es)
|
2016-04-05 |
2019-03-21 |
Janssen Vaccines And Prevention B V |
Vacuna contra vrs
|
|
ES2829272T3
(es)
|
2016-05-12 |
2021-05-31 |
Janssen Vaccines & Prevention Bv |
Promotor bidireccional potente y equilibrado
|
|
DK3464331T3
(da)
|
2016-05-30 |
2021-01-18 |
Janssen Vaccines & Prevention Bv |
Stabiliserede præfusions-rsv f-proteiner
|
|
WO2017220499A1
(en)
|
2016-06-20 |
2017-12-28 |
Janssen Vaccines & Prevention B.V. |
Potent and balanced bidirectional promoter
|
|
JP7229151B2
(ja)
|
2016-07-14 |
2023-02-27 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
Ｈｐｖワクチン
|
|
WO2018049248A1
(en)
|
2016-09-09 |
2018-03-15 |
Icellhealth Consulting Llc |
Oncolytic virus equipped with bispecific engager molecules
|
|
WO2018091680A1
(en)
|
2016-11-18 |
2018-05-24 |
Transgene Sa |
Cowpox-based oncolytic vectors
|
|
ES2905478T3
(es)
|
2016-12-28 |
2022-04-08 |
Transgene Sa |
Virus oncolíticos y moléculas terapéuticas
|
|
AU2018217935B2
(en)
|
2017-02-09 |
2020-04-30 |
Janssen Vaccines & Prevention B.V. |
Potent and short promoter for expression of heterologous genes
|
|
WO2018210871A1
(en)
|
2017-05-17 |
2018-11-22 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against rsv infection
|
|
US11229692B2
(en)
|
2017-05-17 |
2022-01-25 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against RSV infection
|
|
WO2019020543A1
(en)
|
2017-07-28 |
2019-01-31 |
Transgene Sa |
ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
|
|
EA202090738A1
(ru)
|
2017-09-15 |
2020-06-10 |
Янссен Вэксинс Энд Превеншн Б.В. |
Способ безопасного индуцирования иммунитета против rsv
|
|
WO2020011754A1
(en)
|
2018-07-09 |
2020-01-16 |
Transgene |
Chimeric vaccinia viruses
|
|
EP3875119A4
(en)
|
2018-10-30 |
2022-08-31 |
The University of Tokyo |
ONCOLYTIC VIRUS FOR CANCER THERAPY
|
|
PH12021550974A1
(en)
|
2018-11-13 |
2022-05-02 |
Janssen Vaccines & Prevention Bv |
Stablized pre-fusion rsv f proteins
|
|
CN116096732A
(zh)
|
2020-01-31 |
2023-05-09 |
贝斯以色列护理医疗中心有限公司 |
用于预防和治疗冠状病毒感染的组合物和方法-sars-cov-2疫苗
|
|
IL296520A
(en)
|
2020-03-19 |
2022-11-01 |
Trizell Ltd |
Temperature-responsive virus storage system
|
|
EP4178605A1
(en)
|
2020-07-13 |
2023-05-17 |
Transgene |
Treatment of immune depression
|
|
EP4303233A4
(en)
|
2021-02-01 |
2025-05-07 |
St Phi Therapeutics Co., Ltd. |
Targeted protein degradation system and use thereof
|
|
CA3211034A1
(en)
|
2021-02-19 |
2022-08-25 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion rsv fb antigens
|
|
WO2023020939A1
(en)
|
2021-08-17 |
2023-02-23 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
|
WO2023025899A2
(en)
|
2021-08-26 |
2023-03-02 |
Transgene |
Delivery system for targeting genes of the interferon pathway
|
|
WO2023111725A1
(en)
|
2021-12-14 |
2023-06-22 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
|
WO2023213763A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
|
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
|
EP4547705A1
(en)
|
2022-07-01 |
2025-05-07 |
Transgene |
Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
|
|
WO2024038175A1
(en)
|
2022-08-18 |
2024-02-22 |
Transgene |
Chimeric poxviruses
|